MedTrace Logo

Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma

NCT00724568 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2017-06-02

Study results available
· View outcomes & findings →

Summary

This research study is evaluating an investigational combination of four drugs called Revlimid® (lenalidomide), Velcade® (bortezomib), Dexamethasone and Doxil® (RVDD) as a possible treatment for newly diagnosed multiple myeloma.

Conditions

Interventions

DRUG

Lenalidomide

Patients will be treated with Revlimid on days 1-14 in 3-week cycles for 4-8 cycles.

DRUG

Bortezomib

Patients will be treated with Velcade at 1.3 mg/m2 on days 1, 4, 8, and 11

DRUG

Dexamethasone

Patients will be treated with Dexamethasone at 20 mg orally on days of Velcade and the day after for all dose levels.

DRUG

Doxil

Patients will be treated with Doxil on day 4.

Sponsors & Collaborators

  • University of Michigan Rogel Cancer Center

    lead OTHER

Principal Investigators

  • Moshe Talpaz, MD · University of Michigan Rogel Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2009-04-30
Completion
2014-09-03

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00724568 on ClinicalTrials.gov